公司概覽
業務類別 Drug Manufacturers - General
業務概覽 Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
公司地址 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
電話號碼 +1 551 430-6900
傳真號碼 --
公司網頁 https://www.organon.com
員工數量 10000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Daniel Karp Executive Vice President, Corporate Development and Chief Strategy Officer -- 24/04/2026
Mr. Matthew M. Walsh Executive Vice President, Chief Financial Officer and Principal Accounting Officer 美元 919.23K 24/04/2026
Ms. Juliana Papa Drinane Interim Head of Manufacturing and Supply -- 24/04/2026
Mr. Vittorio Nisita Executive Vice President and Head of Enterprise Services and Solutions -- 24/04/2026
Mr. Joseph T. Morrissey, Jr Chief Executive Officer 美元 819.23K 27/04/2026
Mr. Kirke Weaver Executive Vice President, General Counsel and Corporate Secretary 美元 676.92K 24/04/2026
Mr. Aaron Falcione Executive Vice President and Chief Human Resources Officer -- 24/04/2026
Ms. Rachel A. Stahler Executive Vice President and Chief Digital and Growth Officer 美元 706.92K 24/04/2026
Dr. Juan Camilo Arjona Ferreira, M.D. Executive Vice President, Head of Research and Development and Chief Medical Officer 美元 734.62K 24/04/2026
 
董事會成員
董事會 職務 更新日期
Dr. Helene D. Gayle, M.D. Independent Director 24/04/2026
Ms. Shalini Sharp Independent Director 24/04/2026
Mr. Robert A. Essner Lead Independent Director 24/04/2026
Ms. Rochelle B. Lazarus Independent Director 24/04/2026
Ms. Ramona A. Sequeira Independent Director 24/04/2026
Ms. Carrie S. Cox Executive Chairman of the Board 24/04/2026
Dr. Philip Ozuah, M.D.,PhD Independent Director 24/04/2026
Ms. Deborah R. Leone Independent Director 24/04/2026
Dr. Alan Ezekowitz, M.D.,PhD Independent Director 24/04/2026
Ms. Grace Puma Independent Director 24/04/2026
Ms. Cynthia M. Patton Independent Director 24/04/2026
 
所屬ETF (更新日期: 02/05/2026 03:01)
代號 名稱 佔比% 持有日期
AFMCFirst Trust Active Factor Mid Cap ETF0.002%28/04/2026
GVUSGoldman Sachs MktBt Russell LgCpValEqETF0.001%29/04/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.001%27/04/2026
SAAProShares Ultra SmallCap6000.001%28/04/2026
JUSTGoldman Sachs JUST US Large Cap Eq ETF0.001%29/04/2026
ESIXState Street® SPDR® S&P SmCap 600 ESGETF0.001%28/04/2026
MMTMState Street® SPDR® S&P® 1500MomtTiltETF0.0005%28/04/2026
PBSMInvesco PureBeta MSCI USA Small Cap ETF0.0005%31/05/2023
WSGEWarren Street Global Equity ETF0.0004%28/04/2026
SCOWPacer S&P SmCp 600 Qul FCF Aristcrts ETF0.0004%28/04/2026
KBFRInnovator U.S. Small Cap Mgd 10 Bfr ETF0.0004%28/04/2026
AVIEAvantis Inflation Focused Equity ETF0.0001%29/04/2026
AVTMAvantis Total Equity Markets ETF0.00002%29/04/2026
EBILongview Advantage ETF0.00001%28/04/2026
AAUSAlpha Architect US Equity ETF<0.000001%08/08/2025
ABOTAbacus FCF Innovation Leaders ETF<0.000001%04/03/2026
AFLGFirst Trust Active Factor Large Cap ETF<0.000001%07/12/2025
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%06/03/2026
AVKAdvent Convertible & Income Fund<0.000001%31/07/2025
BBMCJPMorgan BetaBuilders US Mid Cap Eq ETF<0.000001%22/12/2025
  1    2    3    4   5    6    7    8  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.